Shanghai Pharmaceuticals subsidiary receives drug registration certificate for Paclitaxel Injection
economy1 d ago
coda.news AI summary
- Shanghai Jinhe Biopharmaceutical Co., Ltd. received the NMPA drug registration certificate for Paclitaxel Injection.
- The drug is approved for production and is used to treat advanced ovarian cancer, breast cancer, and non-small cell lung cancer.
- Approval is expected to help Shanghai Pharmaceuticals expand its market share.
- There is a risk that sales may not meet expectations.
36KrRead original ↗